The Pharmaceuticals and Medical Devices Agency (PMDA) is reviewing new adverse reaction risks for a list of drugs including Takeda Pharmaceutical’s acid reducer Takecab (vonoprazan) - a move that is likely to result in label changes - according to the…
To read the full story
Related Article
- MHLW Orders Label Revisions for Takecab, Clozapine and More
March 20, 2019
REGULATORY
- Measles Cases Surge Past Last Year’s Total, Minister Vows Coordinated Response
April 27, 2026
- H5N1 Pre-Pandemic Flu Vaccine Strain Re-Selected for FY2026 Stockpiling
April 27, 2026
- JIHS Inks MOU with German Network to Boost Infectious Disease Preparedness
April 27, 2026
- Govt Presents Draft Public-Private Investment Roadmap at Growth Strategy WG
April 27, 2026
- LDP Team Urges Patent-Period Price Maintenance, CEA Review in Growth Strategy Proposal
April 27, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





